首页> 美国卫生研究院文献>European Journal of Heart Failure >Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program

【2h】

Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program

机译：慢性心力衰竭患者的肝功能异常和预后：Candesartan的心力衰竭数据：死亡率和发病率降低计划的评估

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

AimsThe prevalence and importance of liver function test (LFT) abnormalities in a large contemporary cohort of heart failure patients have not been systematically evaluated.

机译：目的尚未对当代大型心衰患者队列中肝功能检查（LFT）异常的发生率和重要性进行系统评估。

著录项

期刊名称 European Journal of Heart Failure
作者
Larry A. Allen; G. Michael Felker; Stuart Pocock; John J.V. McMurray; Marc A. Pfeffer; Karl Swedberg; Duolao Wang; Salim Yusuf; Eric L. Michelson; Christopher B. Granger;
展开▼
作者单位

展开▼
年(卷),期 -1(11),2
年度 -1
页码 170–177
总页数 8
原文格式 PDF
正文语种
中图分类心血管疾病;
关键词
Heart failure Bilirubin Liver function tests Hepatic congestion Prognosis Death Laboratory tests;

机译：心力衰竭;胆红素;肝功能检查;肝淤血;预后;死亡;实验室检查;

相似文献

外文文献
中文文献
专利

1. Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. [J] . Allen LA, Felker GM, Pocock S, European journal of heart failure: journal of the Working Group on Heart Failure of the European Society of Cardiology . 2009,第2期

机译：慢性心力衰竭患者的肝功能异常和预后：Candesartan的《心力衰竭：死亡率和发病率降低计划》（CHARM）评估数据。
2. Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program [J] . Larry A. Allen1 G. Michael Felker2* Stuart Pocock3 John J.V. McMurray4 Marc A. Pfeffer5 Karl Swedberg6 Duolao Wang3 Salim Yusuf7 Eric L. Michelson8 and Christopher B. Granger2 for the CHARM Investigators European Journal of Heart Failure . 2009,第2期

机译：慢性心力衰竭患者的肝功能异常和预后：Candesartan的心力衰竭数据：死亡率和发病率降低计划的评估
3. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: Results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program [J] . CastagnoD., SkaliH., TakeuchiM., Journal of the American College of Cardiology . 2012,第20期

机译：广泛的慢性心力衰竭患者心率与预后的关联：CHARM（坎地沙坦治疗心衰：评估死亡率和发病率）计划的结果
4. Clinical characteristics, management, and outcomes of patients with high risk chronic heart failure referred to a heart failure clinic in Saudi Arabia [C] . Waleed M.A. World Congress on Heart Disease. . 2013

机译：高危慢性心力衰竭患者的临床特征，管理和结果提及沙特阿拉伯的心力衰竭诊所
5. Factors associated with adherence in heart failure. A secondary analysis of a large clinical trial: Candesartan in Heart failure -Assessment of Reduction in Mortality and Morbidity (CHARM) [D] . Granger, Bradi B. 2004

机译：与心力衰竭依从性相关的因素。大型临床试验的次要分析：坎地沙坦治疗心力衰竭-死亡率和发病率降低的评估（CHARM）
6. Predictors of Development of Diabetes in Patients With Chronic Heart Failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Program [O] . David Preiss, Sofia Zetterstrand, John J.V. McMurray, 2009

机译：坎地沙坦对心衰患者的死亡率和发病率降低（CHARM）程序进行评估时预测坎地沙坦对慢性心力衰竭患者糖尿病的发展趋势
7. Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program [O] . Allen, Larry A., Felker, G. Michael, Pocock, Stuart, 2009

机译：慢性心力衰竭患者的肝功能异常和预后：Candesartan的心力衰竭数据：死亡率和发病率降低计划的评估

Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program

摘要

著录项

相似文献

相关主题

期刊订阅